Patent · US Active

Therapeutic, prophylactic, and diagnostic agent for cancer, useful for characterizing cancer cells with individual properties

US7902146B2 · kind B2 · utility

2Cited by

4References

7Claims

0Family size

Inventors

Michael Zeppezauer · Scheidt, DE
Hans-Peter Leinenbach · Eisenlohrsweg, AT
Reiner Class · Drexel Hill, US
Cordula Fassbender · Cologne, DE

Key dates

Filing date	Jan 22, 2007
Grant date	Mar 8, 2011
Priority date	—
Expiry date	Jan 16, 2028

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/1709
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A therapeutic or prophylactic agent for cancer is disclosed which damages the membrane and kills cancer cells, in particular of the blood-forming system, having membrane protein aggregates which contain several core histones or largely core-like histones and/or their parts. The therapeutic or prophylactic agent contains at least one pure histone or its active sequence section selected from the group composed of histone H1, H1 subtypes, H2A, H2B, H2A:H2B dimer, H3 and H4, covalent modified histones of the above-mentioned type and/or their active sections and functionally and structurally similar proteins (protamines, histone-like proteins of prokaryotic and archae bacteria).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.